Sodium astatide injection that emits alpha rays through an accelerator has therapeutic potential in treating refractory thyroid cancer without causing damage to normal surrounding cells, according to the team of researchers led by Jun Hatazawa of Osaka university, published in the Journal of Nuclear Medicine
Radioactive iodine that emits beta rays has been used for treatment of thyroid cancer since many years. 5-year survival rates may exceed 90%. However, certain thyroid tumors become resistant to this iodine treatment ("iodine-refractory"), and a breakthrough approach is needed. Many researchers have attempted to develop new methods for treatment of iodine-refractory thyroid cancer; none have shown compelling results--until now.
The researchers used a large accelerator in the Nuclear Physics Research Center and the facilities of the Institute for Radiation Science to successfully manufacture a therapeutic drug, sodium astatide for injection, which emits highly therapeutic alpha rays from At-211 ions.
In the study, mice with thyroid cancer cells showed transient weight loss when they received higher doses of sodium astatide. Notably, mice that received lower doses of sodium astatide showed considerable tumor suppression without weight loss, indicating that fractionated alpha-ray exposure may allow effective treatment without severe side effects.
As a next step, preparations are being made for a clinical trial of sodium astatide therapy for alpha-ray treatment of iodine-refractory thyroid cancer with multiple metastases.
Sodium astatide radiation therapy provides systemic alpha-ray exposure that is expected to be an innovative treatment for a variety of cancers with multiple metastases, including refractory thyroid cancer.
Most importantly, injection of the sodium astatide therapeutic drug may enable breakthrough outpatient treatment of cancerous lesions throughout the body without involving external radiation therapy.